Shots:
- The CHMP has recommended Calquence + bendamustine & rituximab for the treatment of 1L MCL adults, who are ineligible for autologous HSCT; regulatory review is ongoing in Japan & other regions
- Opinion was based on P-III (ECHO) trial assessing the combination vs SoC (bendamustine & rituximab) in 1L MCL pts (≥65yrs.; n=635), which showed improved PFS of 27%, with mPFS of 66.4 vs 49.6mos.; data was presented at EHA 2024
- Calquence (BTK inhibitor, BID, PO) is being evaluated as a monotx. & in combination with SoC chemoimmunotherapy for multiple B-cell blood cancers, incl. CLL, MCL & diffuse LBCL
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca to Highlight Tagrisso’s Clinical Data for NSCLC at ELCC 2025
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
